Midiana (Drospirenone, Ethinylestradiol)

The ethinylestradiol component suppresses the pituitary release of follicle‑stimulating hormone, while drospirenone blocks the luteinizing hormone surge, together preventing ovulation. Drospirenone also thickens cervical mucus and alters the endometrial lining, making implantation unlikely.

The dosage regimen for Midiana is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule must follow the prescriber’s instructions.

Midiana is intended for use only when pregnancy is not present. If pregnancy occurs, the product should be discontinued and alternative contraception considered. Use during breastfeeding should be discussed with a healthcare provider, as hormonal contraceptives may affect milk production and infant exposure.

To place an order, submit an enquiry on the Midiana product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Midiana contains drospirenone, which has anti‑mineralocorticoid and anti‑androgenic properties, potentially offering benefits such as reduced water retention and improvement in acne compared with formulations containing other progestins. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives, while side‑effect profiles may differ.

Midiana tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use after the expiration date.

Midiana is taken orally, usually once daily at the same time each day. The tablets are swallowed whole with water and should not be chewed or broken. Adherence to the daily schedule is important for maintaining contraceptive effectiveness.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms such as unexplained leg pain, chest pain, severe headache, or signs of an allergic reaction.

Midiana is contraindicated in women with a history of thromboembolic events, estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, or known hypersensitivity to any component. It should also be avoided by smokers over the age of 35 and by anyone who is currently pregnant.